Li H - Search Results

1

Deep learning approaches for de novo drug design: An overview.

Wang M, Wang Z, Sun H, Wang J, Shen C, Weng G, Chai X, Li H, Cao D, Hou T. Wang M, et al. Among authors: li h. Curr Opin Struct Biol. 2022 Feb;72:135-144. doi: 10.1016/j.sbi.2021.10.001. Epub 2021 Nov 22. Curr Opin Struct Biol. 2022. PMID: 34823138 Review.

2

Comprehensive assessment of deep generative architectures for de novo drug design.

Wang M, Sun H, Wang J, Pang J, Chai X, Xu L, Li H, Cao D, Hou T. Wang M, et al. Among authors: li h. Brief Bioinform. 2022 Jan 17;23(1):bbab544. doi: 10.1093/bib/bbab544. Brief Bioinform. 2022. PMID: 34929743

3

RELATION: A Deep Generative Model for Structure-Based De Novo Drug Design.

Wang M, Hsieh CY, Wang J, Wang D, Weng G, Shen C, Yao X, Bing Z, Li H, Cao D, Hou T. Wang M, et al. Among authors: li h. J Med Chem. 2022 Jul 14;65(13):9478-9492. doi: 10.1021/acs.jmedchem.2c00732. Epub 2022 Jun 17. J Med Chem. 2022. PMID: 35713420

4

Macrocyclization of linear molecules by deep learning to facilitate macrocyclic drug candidates discovery.

Diao Y, Liu D, Ge H, Zhang R, Jiang K, Bao R, Zhu X, Bi H, Liao W, Chen Z, Zhang K, Wang R, Zhu L, Zhao Z, Hu Q, Li H. Diao Y, et al. Among authors: li h. Nat Commun. 2023 Jul 28;14(1):4552. doi: 10.1038/s41467-023-40219-8. Nat Commun. 2023. PMID: 37507402 Free PMC article.

5

Computational methods for drug design and discovery: focus on China.

Zheng M, Liu X, Xu Y, Li H, Luo C, Jiang H. Zheng M, et al. Among authors: li h. Trends Pharmacol Sci. 2013 Oct;34(10):549-59. doi: 10.1016/j.tips.2013.08.004. Epub 2013 Sep 11. Trends Pharmacol Sci. 2013. PMID: 24035675 Free PMC article. Review.

6

eSHAFTS: Integrated and graphical drug design software based on 3D molecular similarity.

He G, Song Y, Wei W, Wang X, Lu X, Li H. He G, et al. Among authors: li h. J Comput Chem. 2019 Mar 5;40(6):826-838. doi: 10.1002/jcc.25769. J Comput Chem. 2019. PMID: 30623477

7

Deep Learning Based Drug Metabolites Prediction.

Wang D, Liu W, Shen Z, Jiang L, Wang J, Li S, Li H. Wang D, et al. Among authors: li s, li h. Front Pharmacol. 2020 Jan 30;10:1586. doi: 10.3389/fphar.2019.01586. eCollection 2019. Front Pharmacol. 2020. PMID: 32082146 Free PMC article.

8

Discovery, Optimization, and Structure-Activity Relationship Study of Novel and Potent RSK4 Inhibitors as Promising Agents for the Treatment of Esophageal Squamous Cell Carcinoma.

Yuan Y, Xu J, Jiang L, Yu K, Ge Y, Li M, He H, Niu Q, Shi X, Fan L, Chen Z, Zhao Z, Li S, Xu Y, Wang Z, Li H. Yuan Y, et al. Among authors: li s, li h, li m. J Med Chem. 2021 Sep 23;64(18):13572-13587. doi: 10.1021/acs.jmedchem.1c00969. Epub 2021 Sep 9. J Med Chem. 2021. PMID: 34496560

9

2-amido-3-(1H-indol-3-yl)-N-substituted-propanamides as a new class of falcipain-2 inhibitors. 1. Design, synthesis, biological evaluation and binding model studies.

Zhu J, Chen T, Chen L, Lu W, Che P, Huang J, Li H, Li J, Jiang H. Zhu J, et al. Among authors: li j, li h. Molecules. 2009 Jan 21;14(1):494-508. doi: 10.3390/molecules14010494. Molecules. 2009. PMID: 19158658 Free PMC article.

10

2-(3,4-dihydro-4-oxothieno[2,3-d]pyrimidin-2-ylthio) acetamides as a new class of falcipain-2 inhibitors. 3. design, synthesis and biological evaluation.

Zhu J, Chen T, Liu J, Ma R, Lu W, Huang J, Li H, Li J, Jiang H. Zhu J, et al. Among authors: li j, li h. Molecules. 2009 Feb 16;14(2):785-97. doi: 10.3390/molecules14020785. Molecules. 2009. PMID: 19223827 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

112,505 results

Search Page